Survodutide Survodutide, developed jointly by Boehringer Ingelheim and Zealand Pharma, is an investigational long-acting, GCGR/GLP-1R agonist targeting obesity by increasing energy expenditure and reducing food intake and MASH
Crohns Disease: Can affect any part of the digestive tract , from mouth to anus, and often extends deeper into the intestinal wall
There are three GLP-1 FDA decisions expected in early-mid 2026 Eli Lillys Mounjaro with a new indication to reduce the risk of major adverse cardiovascular events (MACE) in patients with T2DM Eli Lillys oral once-daily orforglipron for weight loss Novo Nordisks higher dose (7.2 mg) injectable once-weekly Wegovy for weight loss Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape
Patients should consult with their healthcare provider before starting this medication
Antibody-drug conjugates: principles and opportunities
[1] [4] Tirzepatide (Mounjaro, Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist
